Evidence and Experience in Managing Patients with or at High Risk of ASCVD

Overview

This session, led by two expert faculty, will explore the importance of advancing therapy beyond statins to reduce ASCVD risk. Attendees will gain insights into the latest data on omega-3 fatty acids, their potential impact on clinical practice, and strategies for applying professional society guidelines and expert recommendations to manage patients at high cardiovascular risk effectively.

Learning Objectives

• Explain why escalation of therapy beyond statins with nonstatin therapies is beneficial to reduce ASCVD risk
• Discuss recent data of omega-3 fatty acids and how these data may translate into clinical practice to reduce ASCVD events
• Apply professional society recommendations and expert opinion on a case-by-case basis for patients with or at high risk of ASCVD or at risk of further CV events